drugset
drugset / Trial / NCT06500676

A Study of GFH375 in Patients With Advanced Solid Tumors With KRAS G12D Mutations

NCT06500676 ↗

Phase 1/2 Recruiting 407 enrolled Genfleet Therapeutics (Shanghai) Inc.
NaSingle-groupOpen-labelTreatment

Summary

This is a multicenter, open-label, phase I/II study to explore the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of GFH375 in patients with advanced solid tumors harboring a KRAS G12D mutation.

Timeline

Start
2024-07-09
Primary completion
2028-07-31
Completion
2028-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject GFH375 Small molecule — Oral

Indications

cancer